| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year |
| 26 Aug 2026 |
8-K: Regulation FD Disclosure
GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients. Dave Singh1, Kapil Mayawala2, Victoria Szenes2, Andreas Eich3, Brian Lea... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance |
| 02 Mar 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by or i... |
Loading...